Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Pharma 4.0 Market Growth in 2025?

The expansion of the Pharma 4.0 market has been monumental in recent times. The market, which was valued at $17.99 billion in 2024, is expected to rise to $21.77 billion in 2025, with a compound annual growth rate (CAGR) of 21.0%. The historic growth surge is largely due to elements such as regulatory adherence and assurance of quality, expiration of drug patents and the ensuing generic competition, escalated healthcare spending, the rise in demand for personalized medicine and biologics, as well as the globalization of pharmaceutical markets.

What Is the Forecast for the Pharma 4.0 Market Size Through 2029?

The market size for pharma 4.0 is projected to witness rapid expansion in the upcoming years, culminating in a value of $46.41 billion in 2029 with a CAGR of 20.8%. This growth during the forecast period can be linked to the transition into value-based healthcare paradigms, an aging demographic, and heightened demands for healthcare, as well as a need for tailored medicine and precision therapy. Reform in regulations and healthcare policies, along with an increased focus on patient-centric care and results also contribute to this expansion. The forecast period will likely see trends such as personalized medicine and precision therapeutics, digital health innovations, value-based healthcare paradigms, streamlined regulatory accord and expedited approval processes, and digitization and transparency in the supply chain.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14772&type=smp

What are the Key Market Players in Pharma 4.0 Market and How They’re Evolving?

Major companies operating in the pharma 4.0 market are Alphabet Inc., Microsoft Corporation, Pfizer Inc., Johnson & Johnson, Amazon Web Services Inc., Roche Holding AG, International Business Machines Corporation, Merck & Co. Inc., Cisco Systems Inc., Bristol Myers Squibb Company, Oracle Corporation, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Honeywell International Inc., Fujitsu Limited, ABB Ltd., Siemens Healthineers, GE Healthcare, Lotte Corporation, SAS Institute Inc., Optum Inc., POLARISqb, Syntekabio, Optibrium

What Are the Primary Growth Drivers in the Pharma 4.0 Market?

The escalation in telemedicine and remote patient observation practices is anticipated to boost the pharma 4.0 market’s progression. Telemedicine denotes the method of offering medical assistance and advisory services distantly via telecommunication technology. Remote patient surveillance entails the gathering, transmission, and assessment of patient healthcare information from afar, leveraging technology-enabled devices and systems. The growth of telemedicine and remote patient surveillance can be attributed to technological improvements, rising demand for accessible healthcare facilities, and the requirement for effective management of enduring ailments. These advances play a crucial role in pharma 4.0, promoting patient-centric healthcare, enabling real-time data acquisition for personalized medicine, and improving pharmaceutical firms’ competency to collect patient impressions for drug invention. For example, in August 2022, the Australian Digital Health Agency 2022, a government institution based in Australia, reported that from 13th March 2020 to 31st July 2022, 118.2 million telehealth services were provided to 18 million patients, and over 95,000 practitioners employed telehealth services in 2022. Hence, the extension of telemedicine and remote patient supervision practices is steering the advancement of the pharma 4.0 market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14772&type=smp

What Are the Leading Segments in the Global Pharma 4.0 Industry?

The pharma 4.0 market covered in this report is segmented –

1) By Component: Hardware, Software, Services

2) By Technology: Cloud Computing, Artificial Intelligence (Al), Big Data Analytics, Internet of Things (IoT)

3) By Application: Drug Discovery And Development, Clinical Trials, Manufacturing

4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)

Subsegments:

1) By Hardware: Sensors, Industrial Robots, PLC (Programmable Logic Controllers), IoT Devices, SCADA (Supervisory Control And Data Acquisition) Systems, Other Automation Equipment

2) By Software: Enterprise Resource Planning (ERP) Software, Manufacturing Execution Systems (MES), Lab Information Management Systems (LIMS), Supply Chain Management Software, Predictive Maintenance Software, Data Analytics And Artificial Intelligence (AI) Software, Cloud-based Solutions, Cybersecurity Software

3) By Services: Consulting Services, Integration And Implementation Services, Managed Services, Training And Support Services, Maintenance And Repair Services

What Are the Key Market Trends in the Pharma 4.0 Industry?

Leading firms in the pharma 4.0 market are leveraging cloud-based drug discovery platforms like StarDrop to stay competitive. StarDrop is an online drug discovery service that is hosted on remote servers and can be accessed through the Internet. It enables researchers and pharma companies to conduct drug discovery procedures like compound screening, molecular modelling, and data analysis in a virtual setting. For example, Optibrium Ltd., a biotechnology research firm from the UK, launched a cloud-based version of its widely-used drug discovery platform, StarDrop, in October 2023. The goal of this platform is to increase accessibility and decrease total ownership costs for its users. All features and interactivity of the desktop application are maintained in this version. It enables users to access StarDrop from any device with an internet connection, offering more flexibility for researchers who are working remotely or across several locations. Hosted on Amazon Web Services (AWS), this platform is backed by Optibrium’s ISO 27001-certified information security system, which provides advanced data security. This includes encryption for secure data transfer and protection behind a firewall.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharma-4-0-global-market-report

What Is the Regional Outlook for the Pharma 4.0 Market?

North America was the largest region in the pharma 4.0 market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma 4.0 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14772

This Report Delivers Insight On:

1. How big is the pharma 4.0 market, and how is it changing globally?

2. Who are the major companies in the pharma 4.0 market, and how are they performing?

3. What are the key opportunities and risks in the pharma 4.0 market right now?

4. Which products or customer segments are growing the most in the pharma 4.0 market?

5. What factors are helping or slowing down the growth of the pharma 4.0 market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model